A corporate VC firm that invests strategically on behalf of a biopharmaceutical company invests in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is open to opportunities worldwide.
The firm invests in three indication areas: oncology, immunology, and hematology. The fund is interested in therapeutic, medical device and healthcare IT opportunities in these three areas, but does not invest in diagnostics. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).
The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org